

09/851595


Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

## Certificate of Transmission under 37 CFR 1.8

1 703 872 9306

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office

on 11 October 2002.



Signature

Kerri Pollard Schray

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

## Submitted herewith:

Amendment Transmittal  
Preliminary Amendment and Response to Restriction Requirement  
Change of Attorney Docket No.

(1 pages—in duplicate)  
(3 pages)  
(1 page)

Total including this cover sheet

Pages (6 pages)

TO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Practitioner's Docket No. MPI1999-037P1RCP1M

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gu, Wei  
Application No.: ~~09/891,595~~ 09/851,595  
Filed: May 8, 2001  
For: NOVEL G-PROTEIN COUPLED  
RECEPTORS AND USES THEREFOR

Group No.: 1656  
Examiner: P. M. Mertz

Commissioner for Patents  
Washington, D.C. 20231

## AMENDMENT TRANSMITTAL


1. Transmitted herewith for this application is/are:
- This Amendment Transmittal (1 pages)(in duplicate);
  - Response (3 pages); and
  - Change of Attorney Docket No. (1 page).

## FEE PAYMENT

3. It is believed no fee is due in connection with this Transmittal. However, in the event any extension and/or fee is required, please charge Deposit Account No. 501668.

11 October 2002

MILLENNIUM PHARMACEUTICALS, INC.

By 

Kerri Pollard Schray  
Registration No. 47,066  
75 Sidney Street  
Cambridge, MA 02139  
Telephone (617) 551-3676  
Facsimile (617) 551-8820

## CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

## MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

- ☐ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Address"  
Mailing Label No.

## TRANSMISSION

- ☒ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: 11 October 2002

Kerri Pollard Schray

(type or print name of person certifying)

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

113  
LPPractitioner's Docket No. MPI99-037P1RCPLM

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gu, Wei  
Application No.: 09/811,595  
Filed: May 08, 2001  
For: NOVEL G-PROTEIN COUPLED RECEPTORS AND USES THEREFOR

Group No.: 1646  
Examiner: P.M. Mertz

Commissioner for Patents  
Washington, DC 20231

PRELIMINARY AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

Prior to examination on the merits, entry of the following amendments and remarks is requested.

## IN THE CLAIMS:

Kindly cancel claims 1-22 and add new claims 23-32.

23. An isolated nucleic acid molecule comprising the nucleotide sequence selected from the group consisting of:
- a) a nucleotide sequence which is at least about 90% identical to the nucleotide sequence of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO:12;
- b) SEQ ID NO: 4, SEQ ID NO: 6 or a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: 4 or SEQ ID NO: 6;

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

## MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.  
37 C.F.R. SECTION 1.8(a)

## 37 C.F.R. SECTION 1.10\*

- ☐ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Address"  
Mailing Label No. \_\_\_\_\_

## TRANSMISSION

- ☒ transmitted by facsimile to the Patent and Trademark Office.

Signature



Date: 11 October 2002

Kerri Pollard Schray

(type or print name of person certifying)

\*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

**Practitioner's Docket No. MPI99-037P1RCP1M**

c) SEQ ID NO: 7, SEQ ID NO: 9 or a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: 7 or SEQ ID NO: 9; or

d) SEQ ID NO: 10, SEQ ID NO: 12 or a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: 10 or SEQ ID NO: 12.

24. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 8, or SEQ ID NO: 11, or a nucleotide sequence complementary to a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 8, or SEQ ID NO: 11.

25. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a fusion polypeptide comprising the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 8, or SEQ ID NO: 11, and a heterologous polypeptide.

26. An isolated nucleic acid molecule of any one of claims 23-25, further comprising vector nucleic acid sequences.

27. A host cell containing the nucleic acid molecule of any one of claims 23-25.

28. A host cell containing a nucleic acid molecule of claim 26.

29. The host cell of claim 27 which is a mammalian cell.

30. The host cell of claim 28 which is a mammalian cell.

31. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 8, or SEQ ID NO: 11, comprising culturing the host cell of claim 27 under conditions in which the nucleic acid molecule is expressed.

32. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO: 5, SEQ ID NO: 8 or SEQ ID NO: 11, comprising culturing the host cell of claim 28 under conditions in which the nucleic acid molecule is expressed. --